AI predicts risks of brain diseases based on blood analysis

Canadian researchers from The Montreal Neurological Institute and Hospital and the Ludmer Center for Neuroinformatics and Mental Health at McGill University developed a test based on artificial intelligence technology and used it to find patterns in the blood of patients with neurodegeneration related to molecular composition. Now experts have the opportunity to accurately predict the development of brain diseases. This is reported by the press service of the University.

Neurodegenerative diseases, such as Alzheimer's or Huntington's disease, can develop for years without characteristic symptoms. 

To better understand the stages of progression of neurodegeneration, scientists from Canada decided to analyze blood and brain samples from 1969 deceased patients. Their goal was to find changes at the molecular level, which is characteristic of diseases of the brain. To do this, they developed a special algorithm.

As a result, the test helped experts identify several changes in gene expression over the entire period of neurodegeneration.

These conclusions are very important for understanding the nature of these diseases, which for a long time secretly develop in the human body. In the future, the authors note, this will help doctors make a more accurate forecast of the development of brain diseases, as well as track the body's response to treatment.

Next, the scientists intend to evaluate the test to assess the risks of Parkinson's disease and amyotrophic lateral sclerosis.